ClinicalTrials.gg
Active, not recruitingNCT05406674CisConUpdated Jul 20, 2025

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer

A Phase 2 interventional study of Cisplatin 100 mg/m2 and Cisplatin 40 mg/l in FIGO Stage III Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Carcinoma, sponsored by The Netherlands Cancer Institute. Active, not recruiting at 2 sites in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by The Netherlands Cancer Institute · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing cisplatin in Fallopian Tube Neoplasms — 2 open to participants now, 5 under way, 1 of them phase 3. Cisplatin · Fallopian Tube Neoplasms.

Planned enrollment
6th of 20
40 · median 32
Started
2022
with 1 other
Phase 2
8 of 21
none open now
Registered
20th of 21
by date

Among the 21 studies testing cisplatin in Fallopian Tube Neoplasms, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 in phase 2, and was the 20th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

2 of the 21 studies testing cisplatin in Fallopian Tube Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing cisplatin in Fallopian Tube Neoplasms, or all of them as a file.
02

Study summary

Cytoreductive surgery (CRS) with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is used in current clinical practice in selected patients with advanced ovarian cancer. Clinical evidence for the benefit of HIPEC in ovarian cancer comes from the pivotal phase 3 OVHIPEC trial. Worldwide, two established strategies exist for dosing of HIPEC protocols, which follow either a body surface area (BSA)-based or a concentration-based approach. Since both strategies result in different exposure to intra-peritoneal chemotherapy, we aim to compare the pharmacokinetics and safety of both strategies.

03

Conditions studied

  • FIGO Stage III Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signed and written
  2. age ≥ 18 years
  3. patients eligible for interval cytoreductive surgery

    1. histological proven FIGO stage III primary high grade serous ovarian, fallopian tube, or extra-ovarian cancer
    2. when only cytology is performed to confirm the diagnosis ovarian carcinoma, immunohistochemistry should be performed including keratin 7, keratin 20, p53, PAX8
    3. chemotherapy consists of (at least) 3 courses of carboplatin/paclitaxel
    4. following 2 cycles of chemotherapy no progression should occur
  4. treated with optimal or complete interval cytoreductive surgery
  5. fit for major surgery, 0-2
  6. adequate bone marrow function ( level >5.5 mmol/L; leukocytes >3 x 109/L; >100 x 109 /L)
  7. adequate hepatic function (, AST and \<2.5 times )
  8. adequate renal function ( ≥ 60 ml/min using Cockcroft-Gault formula or 24-hour measurement or ml/min/1,73 m2 using or CKD-EPI)
  9. able to understand the patient information

Exclusion criteria

Exclusion Criteria:

  1. history of previous treated with chemotherapy
  2. opting for fertility-sparing surgery
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Arm A

    Patients in Arm A are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cispaltin-based HIPEC with a dosage of 100 mg/m2

    Drug: Cisplatin 100 mg/m2

  • Experimental
    Arm B

    Patients in Arm B are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cisplatin- based HIPEC with a dosage of 40 mg/L perfusate.

    Drug: Cisplatin 40 mg/l

Interventions

  • DrugCisplatin 100 mg/m2

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin 100 mg/m2 milligram(s)/square meter

    Also known as: LO1XA, NDC 16729-288, SUB07483MIG, PL 20075/0123

  • DrugCisplatin 40 mg/l

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin 40 mg/I milligram(s)/litre

    Also known as: LO1XA, NDC 16729-288, SUB07483MIG, PL 20075/0123

06

What researchers measure

Primary outcomes

  1. Intratumoral platinum (Pt) concentration at the end of perfusion after 90 minutes (in ng/mg wet tissue)

    Time frame: End of perfusion after 90 minutes

Secondary outcomes

  1. Toxicity evaluation (CTCAE 5.0)

    Grade 3-5 will be reported

    Time frame: The occurrence of adverse events will be monitored until 6 weeks after surgery

  2. Platinum (Pt) concentration in normal tissue (in ng/mg wet tissue)

    Time frame: End of perfusion

  3. Platinum (Pt) concentration in tumor tissue after 30 minutes and 60 minutes of perfusion (in ng/mg wet tissue)

    Time frame: After 30 minutes and 60 minutes of perfusion

  4. Concentration versus time curve and area-under-the-curve (AUC) of intra-peritoneal Platinum (Pt) during perfusion

    Time frame: During perfusion

  5. Maximum Concentration (Cmax) Platinum (Pt) in perfusate during perfusion

    Time frame: During perfusion

  6. Time to Maximum Concentration (Tmax) Platinum (Pt) in perfusate during perfusion

    Time frame: During perfusion

  7. Terminal elimination half-life (t1/2) Platinum (Pt) in perfusate during perfusion

    Time frame: During perfusion

  8. Clearance from perfusate at the end of perfusion

    Time frame: End of perfusion

  9. Overall Survival (OS)

    Time frame: Will be evaluated after 3 and 5 years after the last patient last visit

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 98 non-industry phase 2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 54 months is below that.

Counting every sponsor, half of 125 studies reached it within 56 months; a quarter within 42 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 6, 2022
StartActual
Jun 15, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05406674
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Jun 15, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 20, 2025

Study contacts

W. van Driel, MD PhD
principal investigator · NKI-AvL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion